Elsevier

American Heart Journal

Volume 233, March 2021, Pages 1-4
American Heart Journal

Research Letter
Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial

https://doi.org/10.1016/j.ahj.2020.11.003Get rights and content

Recognizing that body surface area (BSA) is a commonly used metric to inform medication dosing across fields of medicine, it is possible that patients with heart failure with reduced ejection fraction (HFrEF) with higher BSA may be more likely to tolerate higher doses of GDMT. Using the HF-ACTION trial, we examined (1) the relationship between BSA and achievement of target dosing of evidence-based beta-blocker and angiotensin-converting enzyme inhibitor (ACEI) therapy, and (2) the associations and interactions between target dosing, clinical outcomes, and BSA.

Section snippets

Disclosures

Dr. Greene has received a Heart Failure Society of America/ Emergency Medicine Foundation Acute Heart Failure Young Investigator Award funded by Novartis; receives research support from the American Heart Association, Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, Novartis; has served on advisory boards for Amgen and Cytokinetics; and serves as a consultant for Amgen and Merck. Dr. Mentz receives research support and honoraria from Abbott, American Regent, Amgen, AstraZeneca, Bayer,

REFERENCES (8)

There are more references available in the full text version of this article.

Cited by (1)

Funding Sources: None.

View full text